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Rats treated with oral dose of 100 mg/kg of fluconazole during
pregnancy had their serum and amniotic fluid quantified for this
drug using a GC/MS method. Fluconazole was extracted with ethyl
acetate from samples and analysed by a GC-MS Shimadzu QP5050A
system using a CBP-5 fused silica capillary column. Tioconazole
was used as internal standard. Calibration curve was linear within
the range 10.0 – 300.0 μg/mL. The limit of quantification was
0.1 μg/mL and no interference was observed in the blank serum
and amniotic liquid. The mean concentrations of the drug in the
serum and amniotic fluid were 206.01 ± 105.25 μg/mL and 125.34
± 65.24 μg/mL, respectively. This procedure showed to be sensitive
and efficient enough for the use in teratogenic studies of fluconazole
and other azole drugs.
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ylmethyl)benzyl alcohol, is a broad-spectrum triazole
antifungal agent, which has shown to be active against
systemic and superficial infections (Richardson et al., 1985).
Studies on the pharmacokinetics of fluconazole showed: rapid
absorption after oral administration, no metabolization,
approximately 80% is excreted unchanged in the urine, and
a wide distribution in several organs in the body (Ripa et al.,
1993; Debruyne and Ryckelynck, 1993). Recently, some
reports pointed out the adverse effects of fluconazole on
pregnancy (King et al., 1998). Cases of newborns with
skeleton and cranium malformations, and heart problems
suggested that high doses of this drug (400 – 800 mg/day)
might be teratogenic (Mastroiacovo et al., 1996; Pursley et
al., 1996; Polifka, Friedman, 1999). Despite the observed
effects on the development of the foetus, there is no evidence
until now about the transference of fluconazole through pla-
centa. Although several analytical chromatographic methods
have been developed to analyse fluconazole in biological fluids
(Wood, Tarbit, 1986; Beijnen et al., 1991; Koks et al., 1995;
Ng et al., 1996; Majcherczyk et al., 2002; Eerkes et al.,
2003), there are no reports of fluconazole quantification in
amniotic liquid. The objective of this study was to develop a
simple assay for determination of fluconazole in serum and
amniotic fluid of rats treated with oral dose of 100 mg/kg of




Fluconazole was obtained from Pfizer (São Paulo,
Brazil) and the internal standard, tioconazole, from Galena
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(China). Ethyl acetate (HPLC grade) was from Burdick
& Jackson, USA) and reagent grade water (Milli-Q®,
Millipor Corp.) was used.
Chromatography
Analyses were performed on a GC-MS Shimadzu
QP5050A instrument employing the following conditions:
Column: CBP-5 (Shimadzu) fused silica capillary column
(30 m long × 0.25 mm i.d. × 0.25 mm film thickness
composed of 5% phenylmethylpolysiloxane) connected to
an ion trap detector operating in EI mode at 70 eV; carrier
gas: He (1 mL/min); injector and ion-source temperatures
were 300 °C and a split ratio of 1:5. Injection volume was
1 mL (ethyl acetate) and the oven temperature was
programmed from 160 °C (isothermal for 1 min), with an
increase of 35 °C/min, to 270 °C, then isothermal for 10
min. Tioconazol, 10.0 µg, was used as internal standard.
Concentrations of fluconazole in the maternal serum and
amniotic fluid samples were derived by interpolation of the
ratio between peak areas in the calibration curve.
Sample collection
Eight pregnant Wistar rats were treated by gavage with
a 20 mg/ml suspension of fluconazole at a dose of 100 mg/kg,
during organogenesis (from the 6th to the 15th gestation day).
On the 15th day, two hours after the last dose of fluconazole,
the rats were anaesthetized by ethyl ether inhalation and the
peritoneal and thoracic cavities were opened. Maternal blood
was collected from the heart and immediately centrifuged at
2500 g for 5 min. Then serum was removed and frozen until
assay. Uteri were dissected longitudinally and the amniotic
fluids from each maternal-fetal unit were collected and frozen
until analysis. The approval for the use of animals and for the
procedures required for the experiments was obtained by the
Ethical Committee for Animal Use in Experimental Studies of
the Universidade Federal de Goiás.
Sample preparation
To both 0.5 mL of maternal serum and amniotic
fluid, 1.0 mL of water was added. The samples were then
extracted with 6 mL of ethyl acetate by vortex-mixing for
one minute. After 10 min centrifugation at 1400 g, 25 oC,
5.0 mL of the organic layer were transferred to a clean
tube and evaporated to dryness under N
2
 (Kim et al.,
1994). The internal standard, 20.0 µL tiocanazole
(5000.0 µg/mL in ethyl acetate), was added to the residue
and the volume was made up to 200.0 µL with ethyl acetate.




The specificity of the assay was examined by
comparing the chromatogram of the drug-free serum
sample with that of standard solution of fluconazole and
tioconazole. Retention times (RT) of fluconazole and
tioconazole were approximately 5.37 and 11.7 min,
respectively. Typical chromatograms are shown in Figure
1. The total run time for each sample injection was about
15 min. There were no interfering peaks in the blank serum
at the retention times of fluconazole and the internal
standard.
Linearity
Standard solutions were prepared by dissolving
fluconazole in ethyl acetate, within a concentration range
of 10.0 – 300.0 µg/mL (n=6). At each concentration level
internal standard, tioconazole (10.0 µg), was added and the
solutions were analysed in triplicate. Calibration curve was
derived by plotting the peak-height ratios of fluconazole
FIGURE 1 - GC chromatogram of fluconazole (concentration 50 mg/ml, RT 5,37 min) and tioconazole (concentration
10 mg/mL, RT 11,7 min).
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and internal standard in standard solutions against the
known concentrations of fluconazole, using linear
regression analysis. The equation obtained was y =
0.19754x – 1.39985, correlation coefficient r = 0.9997.
Limit of quantification
Limit of quantification defined as the lowest
concentration with an R.S.D. = 20% was 0.1 μg/mL.
Recovery
For recovery studies, serum samples were spiked with
fluconazole at three different concentrations (50, 100 and
200 µg/mL) and three samples from each concentration, were
extracted using the assay procedure. After dryness, 20.0 μL
of the internal standard, (5000.0 µg/mL in ethyl acetate), was
added to the residue and the volume was made up to 200.0 µL
with ethyl acetate, 1.0 µL aliquot of the mixture was analysed.
The recovery was calculated from the peak areas of the
spiked samples and the peak areas of standard solutions in the
same concentration ranges. The efficiency of the extraction
was greater than 90% in the three concentrations (Table I).
Precision and accuracy
Blank serum samples were spiked with fluconazole
at three concentration levels (50, 100 and 200 µg/mL), at
each concentration internal standard was added. Six
replicates of each solution were analysed and the
coefficients of variation (C.V.) were calculated using the
mean of the concentrations found and S.D. For this study
the variances were acceptable, with C.V. values below 5%
(Table I). Accuracy (bias) for fluconazole was expressed
as the percentage deviation of observed concentration
from theoretical concentration; the greatest bias was equal
to 3.8% (Table I).
Maternal serum and amniotic fluid samples
Typical GC chromatograms of serum and amniotic fluid
samples of rats treated with fluconazole are shown in Figure 2.
TABLE I - Results obtained from method validation: precision (C.V.), accuracy (bias) and the recovery of fluconazole
from the spiked serum samples
Spiked serum samples Conc. found* C.V. Bias Mean recovery
(µg/mL) (µg/mL) (%) (%) (%)
mean ± S.D.
50 49.4±1.8 3.6 -1.2 92.5±6.7
100 96.2±4.6 4.8 -3.8 93.2±4.9
200 195.3±7.5 3.8 -2.4 91.8±7.3
* Calculated from calibration curve for spiked serum samples (n = 6).
FIGURE 2 - GC Chromatograms of fluconazole (5.37 min) and internal standard (tioconazole, 11.7 min). (A) serum sample
and (B) amniotic liquid sample, obtained from rats treated with fluconazole.
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Table II presents the concentrations of fluconazole
determined in maternal serum and amniotic fluid after two
hours of the last oral administration of the drug. The
treatment lasted ten days (from 6th to 15th day of gestation)
and the mean concentrations of fluconazole in maternal
serum and in amniotic fluid were 206.01 ± 105.25 µg/mL
and 125.34 ± 65.24 µg/mL, respectively.
DISCUSSION
Quantification of fluconazole in serum and amniotic
fluid of Wistar rats was possible using the present method. The
preparation of sample is easy followed by GC/MS analysis
with a simple capillary column. Previous GC assays for
fluconazole quantitative determination described a pre-
treatment of the packed column with benzoyl chloride (Wood,
Tarbit, 1986), or indicated the use of a semi-capillary column
(Beijnen et al., 1991) with low efficiency. In both methods an
electron capture detector was used, which is less selective
than the ion trap deterctor. In the present method, column
deactivation and derivatization of fluconazole were
unnecessary; even so the limit of detection was 0.1 μg/ml.
This fact shows the sensitivity of the proposed method. HPLC
analysis of fluconazole using UV detector (Koks et al., 1995;
Ng et al., 1996; Majcherczyk et al., 2002) showed to be less
sensitive than GC/MS method. Recently a very sensitive
HPLC/MS/MS method (Eerkes et al., 2003) has been
published, however, unfortunately these instruments have not
become commonly available in all laboratories yet.
CONCLUSION
A simple, specific and rapid GC/MS method for the
measurement of fluconazole concentrations, in serum and
amniotic fluid, is described. It offers a suitable alternative
to the existing GC and HPLC techniques and it can be
used to quantify fluconazole and tioconazole in biological
fluids for teratogenic and pharmacokinetic studies.
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RESUMO
Determinação de fluconazol em soro e líquido
amniótico de ratas por cromatografia a gas/
espectrometria de massas (CG/EM)
Soro e líquido amniótico de ratas tratadas com
fluconazol (dose oral de 100 mg/kg) durante a prenhez
foram quantificados para este fármaco usando
cromatografia gasosa acoplada à espectroscopia de
massas (CG/EM). O fluconazol foi extraído das amostras
com acetato de etila e analisado empregando-se um
cromatógrafo CG/EM Shimadzu QP5050A com coluna
capilar de sílica fundida CBP-5. O tioconazol foi utiliza-
do como padrão interno. A curva padrão foi linear no
intervalo das concentrações de 10,0 a 300,0 μg/mL. O
limite de quantificação foi de 0,1 μg/mL e não foi obser-
vada interferência no branco de soro e líquido amniótico.
As concentrações médias do fármaco no soro e líquido
amniótico foram 206,01 ± 105,25 μg/mL e 125,34 ±
65,24 μg/mL, respectivamente. Este procedimento mos-
trou-se sensível e eficiente para ser usado em estudos de
teratogenicidade do fluconazol e outros azóis.
UNITERMOS: Fluconazol. CG/EM. Soro. Líquido
amniótico.
REFERENCES
BEIJNEN, J.H.; MEENHORST, P.L.; GIJN, R.;
HAZELAGER, W.A.; KOKS, C.H.W., UNDERBERG,
W.J.M. Gas chromatographic analysis, with electron
capture detection, of the antifungal drug fluconazole in
microvolumes of human plasma. J. Pharm. Biomed.
Anal., v.9, p.1173-1175, 1991.
TABLE II - Fluconazole concentration detected in serum
and amniotic liquid samples from rats treated at a dose of
100 mg/kg, during organogenesis
Treated Fluconazole Fluconazole
Rats concentration in concentration in
(n=8) serum (mg/mL)  amniotic liquid
(mg/mL)
Rat 1 273.02 170.34
Rat 2 321.41 100.57
Rat 3 126.70 91.55
Rat 4 170.94 157.44
Rat 5 48.55 25.04
Rat 6 107.42 60.70
Rat 7 296.18 194.56
Rat 8 303.86 202.52
mean±S.D. 206.01±105.25 125.34±65.24
Determination of fluconazole in serum and amniotic fluid of rats 227
DEBRUYNE, D.; RYCKELYNCK, J.P. Clinical
pharmacokinetics of fluconazole. Clin. Pharmacok.,
v.24, p.10-27, 1993.
EERKES, A.; SHOU, W.Z.; NAIDONG, W. Liquid/liquid
extraction using 96-well plate format in conjunction with
hydrophilic interaction liquid chromatography-tandem
mass spectrometry method for the analysis of fluconazole
in human plasma. J. Pharm. Biomed. Anal., v. 31, p.917-
928, 2003.
KIM, H.; LAPIGUERA, A.; LIN, C. Gas chromatographic
and high-performance liquid chromatographic methods for
the determination of genazole in biological fluids. J.
Chromatogr. B, v. 655, p.21-26, 1994..
KING, C.T.; ROGERS, P.D.; CHAPMAN, S.W. Antifungal
therapy during pregnancy. Clin. Infect. Dis., v.27, p.1151-
1160, 1998.
KOKS, C.H.W.; ROSING, H.;MEENHORST, P.L.; BULT,
A.; BEIJNEN, J.H. High-performance liquid
chromatographic determination of the antifungal drug
fluconazole in plasma and saliva of human
immunodefiency virus-infected patients. J. Chromatogr.
B, v. 663, p.345-351, 1995.
MAJCHERCZYK, P.A.; MOREILLON, P.;
DECOSTERD, L.A.;SANGLARD, D.; BILLE, J.;
GLAUSER, M.P.; MARCHETTI, O. Single-step
extraction of fluconazole from plasma by ultra-filtration
for the measurement of its free concentration by high
performance liquid chromatography. J. Pharm. Biomed.
Anal., v. 28, p.645-651, 2002.
MASTROIACOVO, P.; MAZZONE, T.;BOTTO, L.D.;
SERAFINI, M.A.; FINARDI, A.; CARAMELLI, L.;
FUSCO, D. Prospective assessment of pregnancy
outcomes after first-trimester exposure to fluconazole.
Am. J. Obstetr. Gynecol., v.175, p.1645-1650, 1996.
NG, T.K.C.; CHAN, R.C.Y.;ADEYEMI-DORO, F.A.B.;
CHEUNG, S.W.; CHENG, A.F.B. Rapid high
performance liquid chromatographic assay for antifungal
agents in human sera. J. Antimicr. Chemother., v. 37,
p.465-472, 1996.
POLIFKA, J.E.; FRIEDMAN, J.M. Clinical teratology:
identifying teratogenic risks in humans. Clin. Genet., v.56,
p.409-420, 1999.
PURSLEY, T.J.; BLOMQUIST, I.K.; ABRAHAM, J.;
ANDERSEN, H.F., BARTLEY, J.A. Fluconazole-
induced congenital anomalies in three infants. Clin. Infect.
Dis., v.22, p.336-340, 1996.
RICHARDSON, K.; BRAMMER, K.W.; MARRIOTT,
M.S.; TROKE, P.F. Activity of UK-49,858, a bis-triazole
derivative, against experimental infections with Candida
albicans and Trichophyton mentagrophytes. Antimicr.
Agents Chemother., v.27, p.832-835, 1985.
RIPA, S.; FERRANTE, L.; PRENNA, M. Pharmacokinetics
of fluconazole in normal volunteers. Chemotherapy, v.39,
p.6-12, 1993.
WOOD, P.R., TARBIT, M.H. Gas chromatographic method
for the determination of fluconazole, a novel antifungal
agent, in human plasma and urine. J. Chromatogr., v.383,
p.179-186, 1986.
Recebido para publicação em 03 de fevereiro de 2004.
Aceito para publicação em 04 de abril de 2005.
